Melatonin: the dawning of a treatment for fibrosis?

Area of Science:

• Biomedical Science
• Molecular Biology
• Pathology

Background:

• Fibrosis is a prevalent pathological response to organ injury and failure, lacking effective therapeutic interventions.
• Excessive extracellular matrix (ECM) deposition characterizes fibrosis, leading to organ dysfunction.

Purpose of the Study:

• To review the multifaceted protective effects of melatonin against fibrosis.
• To elucidate melatonin's role in regulating the distinct phases of the fibrogenic response.
• To highlight melatonin's potential as a therapeutic agent for fibrotic diseases.

Main Methods:

• Comprehensive literature review of studies investigating melatonin's effects on fibrosis.
• Analysis of molecular pathways targeted by melatonin, including antioxidant and anti-inflammatory actions.
• Examination of melatonin's impact on the four major phases of fibrogenesis.

Main Results:

• Melatonin demonstrates significant anti-fibrotic effects across multiple organs, including the heart, liver, lung, and kidney.
• Melatonin regulates all four phases of the fibrogenic response: primary injury, effector cell activation, ECM elaboration, and deposition.
• Melatonin also inhibits the formation of adhesions following surgical procedures.

Conclusions:

• Melatonin exhibits broad-spectrum anti-fibrosis properties through its antioxidant and anti-inflammatory mechanisms.
• Melatonin's ability to modulate key fibrogenic pathways positions it as a promising therapeutic candidate for treating organ fibrosis.
• Further research into melatonin's role in fibrotic conditions is warranted to optimize its clinical application.